PMV Pharma: Making p53 Druggable? $pmvp – Two Natural Cap

PMV Pharma trades below its cash balance even as its oral p53 drug rezatapopt posted a 44.4% response rate in heavily pretreated ovarian-cancer patients.

The company's original ambition, a broad platform attacking any of the more than 25,000 known p53 mutations, has narrowed to a single mutation that affects roughly 3% of ovarian cancers, after the drug failed in RAS-co-mutated tumors and a Keytruda combination study was halted for toxicity. Two Natural Capital, whose position disclosure is not stated in the source report, argues management's $350 million to $420 million U.S. peak-sales estimate implies unrealistic revenue per patient once treatment duration and biomarker-testing limits are factored in.

Ticker: PMVP (PMV Pharma, Inc.)
Research Firm: Two Natural Capital
Report URL: https://www.twonaturalcap.com/p/pmv-pharma-making-p53-druggable-pmvp?ref=shortreport.fyi
Position Disclosure: Not stated in the source report.

Thesis

Two Natural Capital argues rezatapopt may work in a narrow ovarian-cancer niche, but PMV's broader p53 ambitions and commercial math don't hold up.

• Fragmented Target: p53 carries more than 25,000 documented mutations, and even its single most common one appears in only about 5.6% of solid tumors per PMV's own S-1 (page 122), undercutting any tumor-agnostic platform pitch.
• Platform Retreat: PMV's 2020 IPO pitch described a "tumor-agnostic" p53 platform; the report says management later discontinued two earlier-stage candidates to preserve cash.
• RAS Co-Mutation Failure: Rezatapopt "didn't end up working well" in patients whose tumors carried both Y220C and RAS mutations, and its Phase 1 Keytruda combination study was halted for dose-limiting toxicities.
• Pocket Exploit, Not Platform: The Y220C mutation creates an unusual hydrophobic pocket that lets a conventional small molecule bind and restore p53's wild-type form, a mechanism the author says doesn't generalize to p53 broadly.
• Ovarian Niche Math: Phase 2 data show a 44.4% overall response rate in heavily pretreated ovarian cancer (45.5% platinum-resistant, 44% platinum-refractory), in a population where Y220C occurs in about 3% of cases and RAS mutations are reportedly infrequent.
• Per-Patient Revenue Gap: Management's $350 million to $420 million peak-sales range, built on roughly 900 eligible patients, implies about $427,000 of revenue per patient; the author's own model, using $30,000 monthly pricing, seven months of treatment, and 100% penetration, produces only about $190 million.
• Testing Bottleneck: Below-target biomarker-testing usage could limit how many eligible patients are even identified for rezatapopt.
• Cash Squeeze: PMV has cash only through Q2 2027, a runway the report says must cover not just commercialization but ongoing Phase 2 solid-tumor trials and a required confirmatory Phase 3 trial.

Catalysts

• Q1 2027 filing decision: PMV management's planned filing for approval in platinum-resistant/refractory ovarian cancer based on Phase 2 data; approval or rejection would validate or undercut the near-term commercial case.
• Q2 2027 cash runway endpoint: Cash runway ends, per the report, forcing a capital raise that could dilute shareholders or constrain trial funding.
• Additional Phase 2 readouts: Ongoing Phase 2 rezatapopt studies in additional solid-tumor types; positive readouts could widen the addressable market beyond ovarian cancer.
• Confirmatory Phase 3 requirement: A confirmatory Phase 3 trial is required to support any accelerated approval; its design and results will determine whether approval holds.
• Biomarker-testing adoption trend: Higher testing rates would expand the identified eligible patient pool used in peak-sales estimates.

Company Response

The source report does not indicate that PMV Pharma was asked for comment, and no company response is included in the source report.

Notable Details

• Rezatapopt's median duration of response was 8.2 months in Phase 1/2 data, compared with 5.6 months for Corcept's relacorilant in its Phase 2 trial, though the comparison carries cross-trial caveats.
• Kymera developed KT-253, a PROTAC aimed at degrading MDM2 as part of the p53 pathway, but the report says the company put it "on the back burner" in favor of inflammatory-and-immunology candidates.
• Unnamed Chinese companies are cited in the report as having their own p53 candidates in development.
• In a footnote, the author says daraxonrasib's inhibition of wild-type RAS is why "Ben Sasse can be seen with facial wounds in some interviews," an aside illustrating the toxicity tradeoffs facing rival RAS-targeting approaches.

"p53's not only conventionally undruggable, but its most dominant mutation only shows up in ~5.6% of solid tumors."

The author uses this line to frame p53's core problem: even its most common mutation is too fragmented to support an obvious platform strategy.

FAQs

What is PMVP stock and what does PMV Pharma do?

PMVP is the ticker for PMV Pharma, a precision-oncology company that went public in late 2020 describing itself as a developer of small-molecule, tumor-agnostic therapies targeting p53 mutations. Its lead candidate, rezatapopt, targets the Y220C mutation of the p53 gene. The report notes the company currently trades below its own cash balance.

What is PMV Pharma's rezatapopt and how does it work?

Rezatapopt is an oral small molecule designed to fit into a hydrophobic pocket created by the p53 Y220C mutation, restoring the protein toward its normal, wild-type function. In Phase 2 testing in heavily pretreated ovarian-cancer patients, it produced a 44.4% overall response rate, with similar results in platinum-resistant (45.5%) and platinum-refractory (44%) subgroups.

Who is Two Natural Capital and what does its report on PMVP say?

Two Natural Capital is the research firm behind the report analyzed here; its exact position disclosure is not stated in the source material. The firm argues rezatapopt may carve out a real niche in ovarian cancer but says PMV's broader p53-platform ambitions have faltered and management's peak-sales projections are too optimistic given patient counts, pricing, and treatment duration.

Why did PMV Pharma's original p53 platform strategy not pan out?

At its 2020 IPO, PMV described a broader plan to target multiple p53 mutations beyond Y220C. The report says management later discontinued two earlier-stage candidates to conserve cash as biotech funding conditions weakened, narrowing the company's focus to rezatapopt.

Why is p53 considered hard to target with drugs?

p53 is a transcription factor, a class of proteins that generally lack obvious drug-binding pockets, and it carries more than 25,000 distinct mutations. Per PMV's own S-1 filing (page 122), even the single most common p53 mutation appears in only about 5.6% of solid tumors, making a one-drug-fits-all approach difficult.

How did rezatapopt perform outside of ovarian cancer?

The report says rezatapopt "didn't end up working well" in patients whose tumors carried both the Y220C mutation and a RAS mutation, and that a Phase 1 study combining it with Keytruda was halted because of dose-limiting toxicities. These setbacks are cited as reasons the drug's use case has narrowed toward ovarian cancer specifically.

How does the $427,000-per-patient figure factor into the PMVP peak-sales debate?

It's derived by dividing the midpoint of management's $350 million to $420 million U.S. peak-sales estimate by the roughly 900 eligible ovarian-cancer patients the estimate assumes. The report contrasts this with rezatapopt's reported median duration of response of 8.2 months (which applies only to responders) to argue the implied per-patient revenue is unrealistic.

When does PMV Pharma need to raise more capital?

The report states PMV has cash only through Q2 2027, and that any future raise would need to fund not just commercialization of rezatapopt but also ongoing Phase 2 trials in other solid tumors and a confirmatory Phase 3 trial required to support accelerated approval.

Disclaimer: This summary is not primary research and does not constitute investment advice. It is a brief overview of a detailed equity research report authored by the firm, organization, or source referenced in this article or at https://www.twonaturalcap.com/p/pmv-pharma-making-p53-druggable-pmvp, which contains extensive evidence, regulatory filings, and analysis; readers are encouraged to review the full report there for a comprehensive understanding. The content provided in this publication is not authored or originated by us — we act solely as a distributor and do not endorse, verify, or take responsibility for the accuracy, completeness, or reliability of the information presented. This publication is for informational purposes only and should not be construed as legal, business, investment, or tax advice. Always conduct independent due diligence and consult qualified professionals before making any decisions based on the information contained herein. We disclaim all liability for any loss or damage arising from reliance on third-party content, and the views expressed are solely those of the respective source and do not necessarily reflect our own.